BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

Required: PD-L1 (CD274) overexpression (CPS ≥ 1) (CPS ≥ 1)

Subjects should be positive for PD-L1 expression (CPS ≥ 1) in tumor specimens by the central laboratory

Cannot have received: systemic anti-tumor therapy

Exception: for persistent, recurrent or metastatic cervical cancer

no prior systemic anti-tumor therapy for persistent, recurrent or metastatic cervical cancer

Cannot have received: immune checkpoint inhibitor

Any prior treatments targeting the mechanism of tumor immunity, such as immune checkpoint inhibitors (e.g., anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies, etc.) or therapies that target immune co-stimulatory molecules (e.g., antibodies targeting ICOS, CD40, CD137, GITR, OX40, etc.)

Cannot have received: chemotherapy (as radiosensitizer)

Exception: within 14 days before the first dose

prior chemotherapeutic agents for increasing the sensitization to radiotherapy within 14 days before the first dose

Cannot have received: radiotherapy

Exception: within 14 days before the first dose (except for palliative area radiotherapy for bone metastases for which pain cannot be effectively controlled by systemic therapy or local pain relief; radiotherapy area < 5% of bone marrow area)

Prior radiotherapy within 14 days before the first dose. Except for palliative area radiotherapy for bone metastases for which pain cannot be effectively controlled by systemic therapy or local pain relief (radiotherapy area < 5% of bone marrow area)

Cannot have received: traditional Chinese patent medicines or anti-tumor herbal medicines

Exception: within 14 days before the first dose

prior use of traditional Chinese patent medicines or treatment with anti-tumor related functions as specified in the NMPA-approved package inserts within 14 days before the first dose, or Chinese herbal medicines for anti-tumor purposes clearly documented in the medical record